retatrutide mental health Significantly Reduces Visceral Fat in Clinical Trials Retatrutide, an investigational triple hormone

Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug

[DOI] [PMC free article] [PubMed] [Google Scholar] 164.Canadian Anesthesiologists Society CAS medication safety Bulletin

IF requires long-term discipline

21 (Suppl 1), 187 (2015)

MESSENGER messenger